Trial | NCT02693574  Report issue

Title

Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori
Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    74
Comparison Efficacy of 14-day Triple Therapy between Clarithromycin and levofloxacin on the Eradication of Helicobacter Pylori in Syrian population
Study Started
Dec 01
2015
Primary Completion
Jan 28
2017
Study Completion
May 31
2017
Anticipated
Last Update
Mar 21
2017

Drug Clarithromycin

  • Other names: Esomeprazole, Amoxicillin

Drug Levofloxacin

  • Other names: Esomeprazole,Amoxicillin, Amoxicillin

Clarithromycin Active Comparator

Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days

Levofloxacin Experimental

Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days

Criteria 

Inclusion Criteria:

1-Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any of following three methods: I-Positive rapid urease test (CLOtest). II-Histologic evidence of H. pylori by modified Giemsa staining. III-Positive 13C-urea breath test. without prior eradication therapy and are willing to receive therapy.

Exclusion Criteria:

Children and teenagers aged less than 18 years.
Previous eradication treatment for H. pylori.
Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.
History of gastrectomy.
Gastric malignancy, including adenocarcinoma and lymphoma,
Previous allergic reaction to antibiotics (Amoxicillin, Clarithromycin, Levofloxacin) and prompt pump inhibitors (Es-omeprazole).
Contraindication to treatment drugs.
Pregnant or lactating women.
Severe concurrent disease.
Liver cirrhosis.
Chronic kidney disease.
Patients who cannot give informed consent by himself or herself.
No Results Posted